DocGo Inc.
NASDAQ:DCGOMedical - Care Facilities
-$0.02 today
- Market cap
- $70.14M
- Beta
- 1.00
- P/E (TTM)
- -0.3
- EPS (TTM)
- -$1.90
Volume 1.64M
Average 0.87M
DCGO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
DocGo Inc.NASDAQ: DCGO
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$13.93M, compared with -$10.62M a year earlier. Trailing-twelve-month EBITDA was -$156.43M.
Context
- EBITDA amounted to 53.0% of revenue in FY2025, up 45.6 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$14.71M (+91.4%) for the fiscal year ending Dec 2026, a step up from the -474.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$13.93M+87.1% QoQ
- Last fiscal yearDec 2025
- -$170.82M-474.9% YoY
- LTMMar 2026
- -$156.43M-1199.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -31.3% | +73.2% | +104.4 pp |
| 1 year | -474.9% | +91.4% | +566.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (170.82M) USD
- Year-over-year change
- -474.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (170.82M) | -474.9% |
| FY2024 | 2024-12-31 | 45.56M | +39.2% |
| FY2023 | 2023-12-31 | 32.73M | -1.9% |
| FY2022 | 2022-12-31 | 33.35M | +18.8% |
| FY2021 | 2021-12-31 | 28.07M | — |
EBITDA vs competitors
How DCGO compares with its peers on the latest reported figures
- DCGO's LTM Mar 2026 EBITDA of -$156.43M is the lowest of the 9 companies compared; the peer median is -$30.6M.
- Its year-over-year change of -1199.8% is the lowest of 9, against a peer median of -10.5%.
- EBITDA amounts to 51.8% of revenue for DCGO, versus a peer median of 301.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$14.17M | -22.2% | — | 13493.3% | |
| LTM Mar 2026 | -$21.1M | -18.3% | — | 265.8% | |
| LTM Mar 2026 | -$24M | +7.8% | — | 337.0% | |
| LTM Mar 2026 | -$26.64M | -14.1% | — | — | |
| LTM Mar 2026 | -$34.56M | -66.8% | — | — | |
| LTM Mar 2026 | -$37.72M | +25.1% | — | 52.1% | |
| LTM Mar 2026 | -$50.64M | -7.0% | — | 32.2% | |
| LTM Mar 2026 | -$76.13M | +39.6% | — | 455.3% | |
| LTM Mar 2026 | -$156.43M | -1199.8% | — | 51.8% | |
| Peer median (excluding DCGO) | -$30.6M | -10.5% | — | 301.4% | |
Competitors are the stored peer set for DCGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 318.72M | 440.52M | 624.29M | 616.56M | 322.2M |
| Cost of Revenue | 208.97M | 285.79M | 428.91M | 402.98M | 223.44M |
| Gross Profit | 109.75M | 154.72M | 195.38M | 213.57M | 98.76M |
| Gross Margin | 34.4% | 35.1% | 31.3% | 34.6% | 30.7% |
| Research & Development | 3.32M | 5.38M | 10.86M | 11.59M | 13.56M |
| Selling, General & Admin | 83.56M | 116.94M | 153.04M | 157.41M | 158.69M |
| Operating Expenses | 94.39M | 132.89M | 180.33M | 184.89M | 187.91M |
| Depreciation & Amortization | 7.51M | 10.57M | 16.43M | 15.88M | 15.66M |
| EBITDA | 28.07M | 33.35M | 32.73M | 45.56M | (170.82M) |
| EBITDA Margin | 8.8% | 7.6% | 5.2% | 7.4% | -53.0% |
| Operating Income | 15.36M | 21.83M | 15.05M | 28.69M | (89.16M) |
| Operating Margin | 4.8% | 5.0% | 2.4% | 4.7% | -27.7% |
| Interest Income | 0 | 762.69K | 1.68M | 236.95K | 0 |
| Interest Expense | 763.03K | 0 | 0 | 2.17M | 1.01M |
| Other Income / Expenses | 4.44M | 950.26K | 1.24M | (939.72K) | (98.34M) |
| Income Before Tax | 19.8M | 22.78M | 16.29M | 27.75M | (187.5M) |
| Pre-Tax Margin | 6.2% | 5.2% | 2.6% | 4.5% | -58.2% |
| Income Tax Expense | 615.7K | (7.96M) | 6.24M | 14.39M | 8.87M |
| Net Income | 23.74M | 34.58M | 6.86M | 19.99M | (182.4M) |
| Net Margin | 7.4% | 7.9% | 1.1% | 3.2% | -56.6% |
| EPS (Basic) | 0.30 | 0.34 | 0.07 | 0.20 | (1.84) |
| EPS (Diluted) | 0.25 | 0.34 | 0.06 | 0.18 | (1.84) |
| Weighted Avg Shares | 80.29M | 101.23M | 103.51M | 102.4M | 99.07M |
| Weighted Avg Shares (Diluted) | 94.86M | 102.98M | 105.62M | 109.42M | 99.07M |
DocGo Inc.
NASDAQ:DCGO
Intrinsic Alpha fair value
Locked
Current Price
$0.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.